![]() |
市场调查报告书
商品编码
1930155
止鼾器市场规模、占有率、成长及全球产业分析:按类型、应用和地区划分的洞察,2026-2034 年Anti-snoring Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
全球止鼾器市场正经历显着成长,这主要得益于睡眠障碍盛行率的上升以及人们对打鼾健康影响的认识不断提高。预计到 2025 年,该市场规模将达到 11.5 亿美元,到 2026 年将成长至 11.4 亿美元,到 2032 年将达到 20 亿美元,预测期内复合年增长率 (CAGR) 为 7.40%。北美地区在 2025 年将占市场主导地位,市场占有率达 37.88%,这主要归因于阻塞性睡眠呼吸中止症 (OSA) 的高盛行率以及慢性打鼾人群的庞大。
止鼾器是一种非侵入性解决方案,旨在透过在睡眠期间打开呼吸道来减少或预防打鼾。这些装置包括下颚前移装置 (MAD)、舌头固定装置 (TRD)、颏带和鼻扩张器,可有效治疗轻度至中度阻塞性睡眠呼吸中止症 (OSA)。非处方止鼾器日益普及,进一步推动了全球市场成长。
市场由瑞思迈 (ResMed)、费雪派克医疗保健有限公司 (Fisher & Paykel Healthcare Limited) 和 SomnoMed 等主要公司主导,这些公司拥有强大的全球影响力和多元化的产品组合。
市场动态
市场驱动因素
睡眠障碍(例如打鼾和阻塞性睡眠呼吸中止症 (OSA))的盛行率不断上升,是止鼾器市场的主要驱动因素。据估计,全球约有9.36亿30至69岁的成年人患有轻度至重度阻塞性睡眠呼吸中止症(OSA),这推动了对无创、经济实惠且舒适的治疗方案的需求。止鼾设备为侵入且昂贵的正压通气疗法和手术干预提供了一种有效的替代方案。提高舒适度、疗效和患者依从性的技术创新正在推动止鼾设备的进一步普及。
市场限制因子
儘管市场成长,但由于消费者认知度和接受度较低,市场仍面临挑战。许多人并不了解打鼾是一种需要介入的疾病。对止鼾设备不适感和疗效不足的误解也限制了其接受度。此外,发展中国家诊断设施的缺乏和相关知识的匮乏也阻碍了市场渗透。例如,截至2023年,美国40.3%被诊断出患有睡眠呼吸中止症的成年人未尝试过任何治疗。
市场机会
新兴市场为止鼾设备製造商提供了巨大的机会。可支配收入的成长、医疗意识的提高以及诊断设施的改善正在推动亚太地区、拉丁美洲和非洲部分地区等地的需求。各公司正利用本地宣传活动、与医疗服务提供者的策略合作以及价格亲民的产品线来扩大市场覆盖范围并促进产品普及。
市场挑战
与正压通气(PAP)设备以及悬雍垂腭咽成形术(UPPP)和射频消融术等外科手术的竞争构成了一项挑战。 PAP设备由医疗专业人员开立处方,并且通常包含在保险范围内,因此是中重度阻塞性睡眠呼吸中止症(OSA)患者的首选治疗方案。外科手术可以提供长期缓解,并减少对非处方设备的依赖。 2019年,美国进行了约18,526例OSA手术,反映出人们对临床治疗的强烈偏好。
市场趋势
非侵入式、技术驱动的解决方案是关键的市场趋势。整合感测器、人工智慧和蓝牙连接的智慧型装置可实现个人化治疗方案、即时监测和行动应用程式整合。例如,ProSomnus 的 EVO[PH] 装置于 2022 年获得 FDA 批准,它透过在睡眠期间调整下颚位置来提高舒适度和依从性。与远距医疗诊断和可穿戴技术的整合正在扩大市场并吸引註重健康的消费者。
依装置类型
依通路划分
北美:2025年市场规模达4亿美元,预计2026年将达4.3亿美元,引领市场。光是美国一地,由于打鼾的高发生率和治疗率,预计到2026年市场规模将达到4.1亿美元。
欧洲:在成熟的供应链和主要参与者的支持下,预计将以7.4%的复合年增长率增长,到2026年达到3.2亿美元。英国、德国和法国是主要贡献者。
亚太地区:预计2026年将达到2.8亿美元,其中印度和中国分别贡献4,000万美元和1.1亿美元。成长主要受意识提升和医疗基础设施改善的推动。
拉丁美洲:预计到 2026 年将达到 7,000 万美元,主要受 OSA 患者意识提升的推动。
中东和非洲:预计到 2025 年,海湾合作委员会 (GCC) 地区的市场规模将达到 2,000 万美元。
The global anti-snoring devices market is witnessing significant growth, driven by the rising prevalence of sleep disorders and increasing awareness about the health impacts of snoring. The market was valued at USD 1.15 billion in 2025 and is projected to grow to USD 1.14 billion in 2026, reaching USD 2 billion by 2032, reflecting a CAGR of 7.40% over the forecast period. North America dominated the market in 2025 with a 37.88% share, primarily due to high prevalence of obstructive sleep apnea (OSA) and a large population of regular snorers.
Anti-snoring devices are non-invasive solutions that help reduce or prevent snoring by keeping the airway open during sleep. These devices include mandibular advancement devices (MADs), tongue retaining devices (TRDs), chin straps, and nasal dilators, which are also effective in managing mild to moderate OSA. The increasing penetration of over-the-counter anti-snoring devices is further supporting market growth globally.
The market is led by major players such as ResMed, Fisher & Paykel Healthcare Limited, and SomnoMed, who hold a strong global presence and a diversified product portfolio.
Market Dynamics
Market Drivers
The rising prevalence of sleep disorders such as snoring and obstructive sleep apnea is a key driver for anti-snoring devices. Globally, an estimated 936 million adults aged 30-69 have mild to severe OSA, increasing the demand for non-invasive, affordable, and comfortable treatment solutions. Anti-snoring devices offer an effective alternative to airway pressure therapy and surgical interventions, which are often invasive and expensive. Technological innovations that improve comfort, efficacy, and patient compliance further drive adoption.
Market Restraints
Despite growth, the market faces challenges due to limited consumer awareness and adoption. Many individuals are unaware that snoring is a medical condition requiring intervention. Misconceptions regarding discomfort or inefficacy also restrict acceptance. Additionally, the lack of diagnostic facilities and limited knowledge in developing countries hinder market penetration. For example, 40.3% of U.S. adults diagnosed with sleep apnea had not tried any treatment as of 2023.
Market Opportunities
Emerging markets present significant opportunities for anti-snoring device manufacturers. Rising disposable incomes, improved healthcare awareness, and better diagnostic facilities in regions such as Asia Pacific, Latin America, and parts of Africa are fueling demand. Companies are leveraging localized awareness campaigns, strategic partnerships with healthcare providers, and affordable product lines to expand market reach and increase adoption.
Market Challenges
Competition from positive airway pressure (PAP) therapy devices and surgical interventions such as Uvulopalatopharyngoplasty (UPPP) or radiofrequency ablation poses challenges. PAP devices are often prescribed by healthcare professionals and covered by insurance, making them a preferred choice for moderate to severe OSA patients. Surgical interventions offer long-term relief, reducing reliance on over-the-counter devices. In the U.S., there were around 18,526 surgical encounters for OSA in 2019, reflecting strong preference for clinical treatments.
Market Trends
Non-invasive and tech-driven solutions are key market trends. Smart devices incorporating sensors, AI, and Bluetooth connectivity enable personalized treatment plans, real-time monitoring, and integration with mobile apps. Devices like ProSomnus' EVO [PH], FDA-cleared in 2022, offer jaw adjustment during sleep, enhancing comfort and compliance. Remote diagnosis through telemedicine and wearable technology integration are expanding the market and attracting health-conscious consumers.
By Device Type:
By Distribution Channel:
North America: Dominated the market in 2025 with USD 0.4 billion, projected to reach USD 0.43 billion in 2026. The U.S. alone is estimated to account for USD 0.41 billion in 2026 due to high snoring prevalence and treatment rates.
Europe: Projected to grow at a 7.4% CAGR, reaching USD 0.32 billion in 2026, supported by established supply chains and key players. The U.K., Germany, and France are major contributors.
Asia Pacific: Estimated at USD 0.28 billion in 2026, with India and China contributing USD 0.04 billion and 0.11 billion, respectively. Growth is driven by rising awareness and improving healthcare infrastructure.
Latin America: Expected to reach USD 0.07 billion in 2026, with increased awareness among OSA patients.
Middle East & Africa: GCC countries expected to reach USD 0.02 billion in 2025.
Competitive Landscape
Major players include SomnoMed (Australia), ResMed (U.S.), Glidewell (U.S.), Panthera Dental (Canada), Fisher & Paykel Healthcare (New Zealand), ProSomnus Sleep Technologies (U.S.), and others. Companies focus on product innovation, geographic expansion, and awareness campaigns. Strategic collaborations, like Rotech Healthcare and Signifier Medical partnership in 2024, strengthen distribution and product accessibility.
Conclusion
The global anti-snoring devices market is projected to grow from USD 1.15 billion in 2025 to USD 2 billion by 2032, at a CAGR of 7.40%. Growth is fueled by the rising prevalence of sleep disorders, technological innovations in smart and non-invasive devices, and expanding awareness in emerging markets. While challenges remain from limited consumer adoption and competition from PAP therapy and surgical solutions, market opportunities in developing regions and technological advancements position the anti-snoring devices market for sustained growth through 2032.
Segmentation By Device Type, Distribution Channel, and Region
By Device Type * Mandibular Advancement Devices
By Distribution Channel * Hospital Pharmacies
By Geography * North America (By Device Type, Distribution Channel, and Country)